These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17602077)

  • 1. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
    Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
    Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
    J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
    Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.
    Mavroudis D; Bolonakis I; Cornet S; Myllaki G; Kanellou P; Kotsakis A; Galanis A; Nikoloudi I; Spyropoulou M; Menez J; Miconnet I; Niniraki M; Cordopatis P; Kosmatopoulos K; Georgoulias V
    Oncology; 2006; 70(4):306-14. PubMed ID: 17047402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
    Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
    Camps C; Sirera R; Bremnes RM; Ródenas V; Blasco A; Safont MJ; Garde J; Juarez A; Caballero C; Sanchez JJ; Taron M; Rosell R
    Anticancer Res; 2006; 26(6C):4905-9. PubMed ID: 17214360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients.
    Franco-Molina MA; Mendoza-Gamboa E; Zapata-Benavides P; Vera-García ME; Castillo-Tello P; García de la Fuente A; Mendoza RD; Garza RG; Támez-Guerra RS; Rodríguez-Padilla C
    Cytotherapy; 2008; 10(5):490-6. PubMed ID: 18821359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
    Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
    J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.